Agios Pharmaceuticals Stock News

Tibsovo sales, after weakness during launch, are ramping nicely. The therapy's label is likely to continue to be expanded for IDH1 mutant cancers.

A number of research firms have changed their ratings and price targets for Agios Pharmaceuticals (NASDAQ: AGIO): 8/1/2020 – Agios Pharmaceuticals was downgraded by analysts at BidaskClub from a “

CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced t

Creative Planning acquired a new position in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission.

Canaccord Genuity reiterated their buy rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research report released on Friday, AnalystRatings.com reports. They currently have a $72.00 target

With me on the call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Darrin Miles, our Senior Vice President of US Commercial

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2020 Results Earnings Conference Call July 30, 2020, 08:00 AM ET Company Participants Holly Manning - Director of Investor Relations Jacqualyn Fouse - Chie

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 7.75% and 5.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

– Second Quarter TIBSOVO® Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million – – Significant Clinical Progress for First-in-Cl

The following slide deck was published by Agios Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings call..

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ABMD) Adamis Pharmaceuticals Corp (NASDAQ: ADMP) Annexon...

The major U.S. benchmarks are acting well technically, though amid increasingly sideways late-July price action, writes Michael Ashbaugh.

Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks. Although there were promising updates from...

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Technically speaking, the U.S. benchmarks’ bigger-picture backdrop remains bullish, and continues to strengthen, amid recently receding volatility, writes...